Patents by Inventor Stanley C. Jordan

Stanley C. Jordan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240124573
    Abstract: Novel therapeutic protocols are provided relating to the use of an anti-IL-6 antibody, e.g., Clazakizumab, in order to prevent, stabilize, reduce or arrest antibody mediated rejection responses in patients receiving solid organ transplants, e.g., patients receiving transplanted kidney, heart, liver, lungs, pancreas, intestines or combinations of any of the foregoing. Also novel therapeutic protocols are provided pertaining to the use of an anti-IL-6 antibody, e.g., Clazakizumab, as part of a desensitization protocol for treating highly sensitized subjects waiting for and/or after allograft transplants, e.g., patients who are to receive solid organ transplants, e.g., kidney, heart, liver, lungs, pancreas, intestines, skin or combinations of any of the foregoing. The foregoing treatments may be effected in combination with one or more other immunosuppressant regimens or other desensitization procedures.
    Type: Application
    Filed: August 10, 2023
    Publication date: April 18, 2024
    Applicants: VITAERIS, INC., CEDARS-SINAI MEDICAL CENTER
    Inventors: Kevin CHOW, Edward CHONG, Nuala MOONEY, Julien LION, Stanley C. JORDAN
  • Publication number: 20240050541
    Abstract: The present invention describes method for reducing Delayed Graft Function (DGF) and Ischemia/Reperfusion Injury (IRI) by intra-renal infusion of a C1 esterase inhibitor.
    Type: Application
    Filed: December 21, 2021
    Publication date: February 15, 2024
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Stanley C. Jordan, Noriko Ammerman, Ashley Vo, Irene Kim, Sanjeev Kumar
  • Publication number: 20220288202
    Abstract: The present invention provides for methods and uses of (i) an IL-6 inhibitor or IL-6R inhibitor, or both; and (ii) CT-LA-4 or CTLA-4 fusion proteins for immunosuppression and/or immunomodulation in a solid organ transplant recipient. Various embodiments of the method comprise administering an IL-6 inhibitor or IL-6R inhibitor, or both to the recipient; and administering a or CTLA-4 fusion protein such as CTLA4-Ig to the recipient and may further include administration or use of a calcineurin inhibitor.
    Type: Application
    Filed: September 4, 2020
    Publication date: September 15, 2022
    Applicant: Cedars-Sinai Medical Center
    Inventors: Stanley C. Jordan, Ashley Vo, Noriko Ammerman, Edmund Huang, Irene Kim
  • Publication number: 20220135695
    Abstract: Methods and systems for desensitizing a human leukocyte antigen (HLA) sensitized subject to prepare for an organ transplant with an improved transplant survival and function, and/or treating or reducing the likelihood of antibody mediated rejection (ABMR) of an organ transplant in a subject are provided, generally including administering an effective amount of an anti-CD38 antibody or a CD38-targeting therapy to reduce the symptoms or ABMR or HLA levels. The subject in the methods may have developed or is experience drug-resistant sensitization, and to whom standard techniques like intravenous immunoglobulin and plasmapheresis are ineffective.
    Type: Application
    Filed: March 9, 2020
    Publication date: May 5, 2022
    Applicant: Cedars-Sinai Medical Center
    Inventors: Stanley C. JORDAN, Noriko AMMERMAN, Ashley VO, Mieko TOYODA, Robert VESCIO
  • Publication number: 20220073605
    Abstract: Described herein are methods for treating antibody mediated rejection (ABMR), especially chronic active ABMR (cABMR), of transplanted organs using clazakizumab Human kidney transplant recipients with biopsy-proven cABMR, transplant glomerulopathy and who are donor-specific antibody positive showed stabilization of renal function and lowered DSA levels following clazakizumab treatment. The estimated glomerular filtration rate of the patients at six, 12 or even 18 months were stabilized, inflammatory markers of cABMR were reduced or stabilized, and inflammatory blood markers were reduced, since clazakizumab treatment.
    Type: Application
    Filed: December 20, 2019
    Publication date: March 10, 2022
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Stanley C. JORDAN, Ashley A. VO, Noriko AMMERMAN
  • Publication number: 20210395358
    Abstract: Methods for desensitization of patients in need of organ transplant are provided Human leukocyte antigen-sensitized patients awaiting incompatible kidney transplant have been treated with clazakizumab to show reduced or eliminated levels of donor-specific antibodies and an improved transplant rate Clazakizumab and variants are provided for use in various embodiments of the methods. In some embodiments, clazakizumab, or its variants, is administered simultaneously or sequentially with intravenous immunoglobulin.
    Type: Application
    Filed: November 8, 2019
    Publication date: December 23, 2021
    Applicant: Cedars-Sinai Medical Center
    Inventors: Stanley C. JORDAN, Ashley VO, Noriko AMMERMAN, Jua CHOI
  • Publication number: 20210070853
    Abstract: Novel therapeutic protocols are provided relating to the use of an anti-IL-6 antibody, e.g., Clazakizumab in order to prevent, stabilize, reduce or arrest antibody mediated rejection responses in patients receiving solid organ transplants, e.g., patients receiving transplanted kidney, heart, liver, lungs, pancreas, intestines or combinations of any of the foregoing. Also novel therapeutic protocols are provided pertaining to the use of an anti-IL-6 antibody, e.g., Clazakizumab as part of a desensitization protocol for treating highly sensitized subjects waiting for and/or after allograft transplants, e.g., patients who are to receive solid organ transplants, e.g., kidney, heart, liver, lungs, pancreas, intestines, skin or combinations of any of the foregoing. The foregoing treatments may be effected in combination with one or more other immunosuppressant regimens or other desensitization procedures.
    Type: Application
    Filed: January 4, 2019
    Publication date: March 11, 2021
    Inventors: Kevin CHOW, Edward CHONG, Nuala MOONEY, Julien LION, Stanley C. JORDAN
  • Publication number: 20170174760
    Abstract: Described herein are methods for treating antibody mediated rejection of transplanted organs using inhibitors of IL-6. In one embodiment, the IL-6 inhibitor is Tocilizumab and is administered simultaneously or sequentially with intravenous immunoglobulin (IVIG).
    Type: Application
    Filed: March 2, 2017
    Publication date: June 22, 2017
    Applicant: Cedars-Sinai Medical Center
    Inventors: Stanley C. Jordan, Ashley Vo, Jua Choi
  • Publication number: 20170022280
    Abstract: Described herein are methods for treating antibody mediated rejection of transplanted organs using inhibitors of IL-6. In one embodiment, the IL-6 inhibitor is Tocilizumab and is administered simultaneously or sequentially with intravenous immunoglobulin (IVIG).
    Type: Application
    Filed: July 25, 2016
    Publication date: January 26, 2017
    Applicant: Cedars-Sinai Medical Center
    Inventors: Stanley C. Jordan, Ashley Vo, Jua Choi
  • Patent number: 6171585
    Abstract: Methods are provided for transplanting a histoincompatible organ allograft in a subject, methods for enhancing organ allograft survival in a subject, methods for reducing the amount of anti-HLA alloantibodies in a transplant candidate and methods to make candidate less susceptible to rejection.
    Type: Grant
    Filed: September 26, 1994
    Date of Patent: January 9, 2001
    Assignee: Cedars-Sinai Medical Center
    Inventors: Stanley C. Jordan, Dolly B. Tyan